Response to PD-1 Blockade in Patients with Mismatch Repair Deficient Colorectal Cancer
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 16-003443
Sponsor Protocol Number: 16-003443
About this study
This study will assess the efficacy and outcomes of PD-1 blockade in patients with mismatch repair deficient colorectal cancer.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
-
All patients with mismatch repair deficient colorectal cancer receiving pembrolizumab from June 1, 2015 through April 20, 2016 at Mayo Clinic Rochester.
-
All patients with mismatch repair deficient colorectal cancer receiving pembrolizumab from April 21, 2016 to April 20, 2018.
Exclusion Criteria:
-
None
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Axel Grothey, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available